Neurocrine Biosciences (NBIX) Financial Ratios: P/E, ROE & More

Neurocrine Biosciences (NBIX) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Neurocrine Biosciences had a P/E ratio of 29.55 (down from 40.49), return on equity of 16.4% (up from 14.2%), debt-to-equity of 0.14 (down from 0.18) and a current ratio of 3.39 (down from 3.40). A current ratio of 3.39 means current assets exceed current liabilities.

Neurocrine Biosciences Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Valuation Ratios
P/E Ratio	29.55	40.49	51.84	74.32	90.18	21.99
Forward P/E	15.87	18.15	21.34	22.53	24.55	22.30
P/S Ratio	4.94	5.87	6.86	7.71	7.13	8.56
P/B Ratio	4.35	5.34	5.80	6.72	5.88	7.95
Price/Tangible Book	4.35	5.34	5.91	6.89	5.88	7.95
Price/FCF	18.89	24.80	35.80	35.56	34.66	41.15
Price/OCF	18.07	23.21	33.20	33.83	31.50	39.19
PEG Ratio	0.75	0.31	0.65	0.66	1.12	0.37
Enterprise Value Ratios
EV/Revenue	4.72	5.47	6.42	7.37	6.85	8.15
EV/EBITDA	20.26	20.64	29.14	41.44	35.51	25.37
EV/EBIT	21.22	21.57	30.71	44.04	37.38	26.04
EV/FCF	18.04	23.11	33.53	33.96	33.32	39.19
Profitability & Returns
Return on Equity (ROE)	16.38%	14.16%	12.68%	10.03%	7.17%	46.20%
Return on Assets (ROA)	9.53%	10.71%	8.78%	7.01%	6.82%	13.46%
Return on Invested Capital (ROIC)	20.50%	23.31%	22.75%	17.26%	19.95%	54.61%
Return on Capital Employed (ROCE)	16.40%	18.60%	15.20%	13.60%	11.40%	21.20%
Leverage & Solvency Ratios
Debt/Equity	0.14	0.18	0.19	0.15	0.32	0.37
Debt/EBITDA	0.65	0.68	0.99	0.94	1.88	1.19
Debt/FCF	0.63	0.82	1.19	0.81	1.89	1.90
Liquidity Ratios
Current Ratio	3.39	3.40	2.45	2.70	3.96	5.45
Quick Ratio	2.92	3.06	2.25	2.49	3.65	5.14
Efficiency Ratios
Asset Turnover	0.69	0.68	0.67	0.67	0.59	0.69
Inventory Turnover	16.90	15.99	16.48	14.85	11.71	12.59
Yield & Distribution Ratios
Earnings Yield	3.38%	2.47%	1.93%	1.35%	1.11%	4.55%
FCF Yield	5.29%	4.03%	2.79%	2.81%	2.89%	2.43%
Buyback Yield	1.16%	-2.67%	-2.12%	-1.02%	-0.10%	-2.19%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Neurocrine Biosciences Financial Ratios

What is Neurocrine Biosciences's P/E ratio?

Neurocrine Biosciences's P/E ratio was 29.55 for fiscal 2025 (period ended Dec 31, 2025). It was 40.49 a year earlier.

What is Neurocrine Biosciences's return on equity?

Neurocrine Biosciences's return on equity (ROE) was 16.4% for fiscal 2025 (period ended Dec 31, 2025). It was 14.2% a year earlier.

What is Neurocrine Biosciences's debt-to-equity ratio?

Neurocrine Biosciences's debt-to-equity ratio was 0.14 for fiscal 2025 (period ended Dec 31, 2025). It was 0.18 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition